Gastric cancer: the role of insulin‐like growth factor 2 (IGF 2) and its receptors (IGF 1R and M6‐P/IGF 2R)
Authors:
- 2 September 2003
- journal article
- research article
- Published by Wiley in The Journal of Pathology
- Vol. 201 (3) , 430-438
Abstract
Insulin‐like growth factor 2 (IGF 2) appears to be involved in the progression of many tumours. It binds to at least two different types of receptor: IGF type 1 (IGF 1R) and mannose 6‐phosphate/IGF type 2 (M6‐P/IGF 2R). Ligand binding to IGF 1R provokes mitogenic and anti‐apoptotic effects. M6‐P/IGF 2R has a tumour suppressor function—it mediates IGF 2 degradation. Mutation of M6‐P/IGF 2R causes both diminished growth suppression and augmented growth stimulation. The aim of this study was to investigate the role of IGF 2 and its receptors (IGF 1R and IGF 2R) in human gastric cancer. The expression of IGF 2 and its receptors was measured in order to analyse the possible correlation between the activity of these genes and cell proliferation in two different gastric tumour types: diffuse and intestinal. The effect of IGF 1 receptor blockage on cell proliferation and anchorage‐independent cell growth was also examined. Increased expression of IGF 2 and IGF 1R genes (at the mRNA and protein level) was found in gastric cancer when compared with non‐tumour tissue. Furthermore, there was a significant difference between IGF 2 expression in the more aggressive diffuse type and that in the intestinal type of gastric cancer. Moreover, the IGF 2 peptide level in the culture media obtained from the diffuse type of cancer cells was significantly higher when compared with the intestinal type. The level of IGF 2 peptide in the conditioned media strongly correlated with [ 3 H]thymidine incorporation and cell proliferation. On the contrary, IGF 2R mRNA expression was much higher in the intestinal type of cancer than in the diffuse type. In addition, IGF 2R protein expression was substantially lower with progression of the diffuse cancer type to a higher stage. The αIR3 monoclonal antibody strongly inhibited [ 3 H]thymidine incorporation and decreased the number of colonies in soft agar of cells overexpressing IGF 2. These findings suggest that members of the IGF family are involved in the pathogenesis of gastric cancer, probably by autocrine/paracrine stimulation of cell growth. Such tumours might be excellent candidates for therapeutic strategies aimed at interference with this pathway. Copyright © 2003 John Wiley & Sons, Ltd.Keywords
This publication has 28 references indexed in Scilit:
- Mannose 6-phosphate/insulin-like growth factor 2 receptor (M6P/IGF2R) variants in American and Japanese populationsHuman Mutation, 2001
- Microsatellite instability in patients with multiple primary cancers of the gastrointestinal tractGut, 2000
- M6P/IGF2R is mutated in squamous cell carcinoma of the lungOncogene, 2000
- Involvement of IGF-II in human cancerJournal of Endocrinology, 1996
- Human tumour bank in Croatia: a possible model for a small bank as part of the future European tumour bank networkEuropean Journal of Cancer, 1994
- Blockade of the insulin‐like growth‐factor‐I receptor inhibits growth of human colorectal cancer cells: Evidence of a functional IGF‐II‐mediated autocrine loopInternational Journal of Cancer, 1994
- STRUCTURE AND FUNCTION OF THE MANNOSE 6-PHOSPHATE/INSULINLIKE GROWTH FACTOR II RECEPTORSAnnual Review of Biochemistry, 1992
- Expression of the genes encoding the insulin-like growth factors and their receptors in the human ovary [published erratum appears in J Clin Endocrinol Metab 1993 May;76(5):1343]The Journal of Clinical Endocrinology & Metabolism, 1992
- Interference of the IGF system as a strategy to inhibit breast cancer growthBreast Cancer Research and Treatment, 1992
- Signal transmission by the insulin-like growth factorsCell, 1989